The Diagnosis, Biomarker Identification And Measurement Of Drug Efficacy In Mental Illness And Neurological Conditions.
Funder
National Health and Medical Research Council
Funding Amount
$119,050.00
Summary
Globally, 2 billion people suffer from a neuropsychiatric illness. The cost is more than US$2 trillion a year. Hampering early intervention is the current lack of definitive, quantitative techniques for diagnosis and measurement of treatment efficacy. This research will determine whether the disease fingerprints produced by a new technique, EVestG, are diagnostically unique (to schizophrenia, depression and Parkinson's disease) and sensitive to disease progression and treatment response.